Navigation Links
Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy
Date:3/20/2009

ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland

New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer and Nutrition in Zurich shows that palonosetron, a second generation 5-HT3 receptor antagonist, warrants adequate caloric intake in oncology patients receiving high emetogenic chemotherapy (HEC). The result comes from an innovative study conducted in the Oncology Institute of Ospedale V. Fazzi of Lecce, Italy, by the research team of Dr. Vito Lorusso. The findings confirmed the efficacy of a single dose of palonosetron and dexamethasone to control chemotherapy-induced nausea and vomiting (CINV) episodes in patients treated with HEC (cisplatin and/or epirubicin and/or iphosphamide) for soft tissue sarcoma: 76% of the patients achieved complete response (no vomiting, no use of rescue medication), 74% complete control (complete response and no more than mild nausea), in the 7-day period following chemotherapy, after palonosetron treatment.

Moreover, the results demonstrated that patients with no vomiting and without nausea had a median daily food intake of 1500 Kcal and 1600 Kcal in the acute and delayed period respectively, which is an adequate caloric consumption. "Palonosetron not only confirms its ability to control nausea," Dr. Lorusso commented. "But considering the relevance of a correct nutritional status for cancer patients, it also demonstrates to allow an adequate caloric consumption, in the 7 day period following chemotherapy. Moreover this benefit prolonged over the monitored period, allowing patients to avoid chemot
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
2. Imagenetix Reports Results of Offer to Extend Warrants
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
9. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
10. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
(Date:12/13/2014)... Taiwan (PRWEB) December 12, 2014 Trend ... indicators in overall global economic growth, Eugene Arthurs, CEO ... photonics , said in a featured talk at OPTIC ... December at the National Chung Hsing University in Taichung. ... being integrated into future energy supplies and soon to ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
... July 9 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced it has obtained new ... of the ATS Open,Pivot(R) Mechanical Heart Valve., ... Open Pivot valve was implanted in Lausanne, Switzerland,on ...
... Wash., July 9 CellCyte Genetics,Corporation (CellCyte) (OTC ... to provide strategic investment and financial advice and,services. ... its two,core platform technologies and will work with ... development and commercialization of,CellCyte,s cell expander and stem ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today proudly ... General Manager of WuXi AppTec,s Atlanta Operations, one ... Inc., has been invited,to join the Association for ...
Cached Biology Technology:ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 2WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... could save thousands of lives a year, University of Utah ... disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis ... that millions of people take to control high cholesterol. ... in a pilot trial with people, statins could provide a ...
... Two international teams of researchers have made significant gains ... skin condition that can be debilitating in some patients. ... two studies published this week in the advance online ... studies help us get closer to realizing the promise ...
... (NIH) has awarded three contracts for pilot projects ... to medium-sized clinical studies. Each of the two-year ... $4 million, represents a collaboration among individuals at ... and Translational Science Awards (CTSA). Administered by the ...
Cached Biology News:Statins may treat blood vessel disorder that can lead to fatal strokes 2Statins may treat blood vessel disorder that can lead to fatal strokes 3Scientists uncover new genetic variations linked to psoriasis 2Scientists uncover new genetic variations linked to psoriasis 33 new informatics pilot projects to aid clinical and translational scientists nationwide 2
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Image Analysis Software. PC Version of NIH Image....
Biology Products: